Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | KRAS | P01116 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 13/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30071461 | 0.90 | USP30 (0.49) | L3MBTL1PTGS2USP30NR1H2CCNB2 | |
| SCHEMBL3371321 | 0.90 | USP30 (0.49) | L3MBTL1PTGS2USP30NR1H2CCNB2 | |
| SCHEMBL22529438 | 0.87 | MCL1 (0.47) | MCL1USP30NR1H2CCNB2CDK1 | |
| SCHEMBL1565970 | 0.87 | MCL1 (0.57) | MCL1USP30NR1H2CCNB2CDK1 | |
| SCHEMBL1313682 | 0.86 | NOD2 (0.45) | MCL1USP30NR1H2CCNB2CDK1 | |
| SCHEMBL29631943 | 0.86 | L3MBTL1 (0.60) | L3MBTL1PTGS2NR1H2 | |
| SCHEMBL30597746 | 0.86 | L3MBTL1 (0.44) | L3MBTL1PTGS2NR1H2 | |
| SCHEMBL29631941 | 0.86 | MAPT (0.46) | L3MBTL1PTGS2NR1H2 | |
| SCHEMBL19013038 | 0.86 | MAPT (0.46) | L3MBTL1PTGS2NR1H2 | |
| SCHEMBL19013605 | 0.86 | L3MBTL1 (0.60) | L3MBTL1PTGS2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680247-A1 | DPP1 INHIBITORS WITH POLYCYCLIC LINKERS AND USES THEREOF | Insmed Incorporated (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| WO-2024192416-A1 | DPP1 INHIBITORS WITH POLYCYCLIC LINKERS AND USES THEREOF | INSMED INCORPORATED (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20180370972-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2018-12-27 | — | — | US | disclosed |
| WO-2017106352-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| EP-1556034-B1 | INDOLE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LTD (GB) | 2008-04-16 | — | — | EP | disclosed |
| EP-1556034-B1 | INDOLE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LTD (GB) | 2008-04-16 | — | — | EP | disclosed |
| US-7183294-B2 | Indole derivatives useful for the treatment of diseases | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183294-B2 | Indole derivatives useful for the treatment of diseases | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183294-B2 | Indole derivatives useful for the treatment of diseases | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7138527-B2 | Inflammatory, allergic and respiratory disorders; beta 2 adrenoceptors agonists; such as 5-(-2-((-2-hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl)amino)propyl) -N-(2-methoxybenzyl)-1H-indole-2-carboxamide | PFIZER INC. (US) | 2006-11-21 | — | — | US | disclosed |
| WO-2005092841-A1 | COMPOUNDS HAVING BETA-AGONIST ACTIVITY | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| US-20050085526-A1 | Indole derivatives useful for the treatment of diseases | BROWN ALAN D (GB) | 2005-04-21 | — | — | US | disclosed |
| US-6844362-B2 | Indole derivatives useful for the treatment of diseases | PFIZER INC (US) | 2005-01-18 | — | — | US | disclosed |
| US-20040235833-A1 | Indole derivatives useful for the treatment of diseases | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| EP-1440966-A1 | Indole derivatives useful for the treatment of diseases | Pfizer Limited (GB) | 2004-07-28 | — | — | EP | disclosed |
| US-20040116503-A1 | Indole derivatives useful for the treatment of diseases | PFIZER INC. | 2004-06-17 | — | — | US | disclosed |
| EP-1407769-A1 | Indole derivatives as beta-2 agonists | Pfizer Limited (GB) | 2004-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | MCL1 3561/4885L3MBTL1 2685/4885PTGS2 1332/4885 |
| US-20050085526-A1 | Indole derivatives useful for the treatment of diseases | IDO1, IDO2, INMT | MCL1 2646/4885L3MBTL1 3758/4885PTGS2 102/4885 |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | MCL1 3561/4885L3MBTL1 2685/4885PTGS2 1332/4885 |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | MTHFD2, MTHFD1, NUDT15 | MCL1 3561/4885L3MBTL1 2685/4885PTGS2 1332/4885 |
| US-20180370972-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | MTHFD2, MTHFD1, NUDT15 | MCL1 3561/4885L3MBTL1 2685/4885PTGS2 1332/4885 |
| US-20040235833-A1 | Indole derivatives useful for the treatment of diseases | IDO1, IDO2, INMT | MCL1 2646/4885L3MBTL1 3758/4885PTGS2 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.